Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 845-850

  Gockel, Ines ^a   Moehler, Markus ^a   Frerichs, Kirsten ^a   Drescher, Daniel ^a   Trinh, Tran Tong ^a   Duenschede, Friedrich ^a   Borschitz, Thomas ^a   Schimanski, Katrin ^a   Biesterfeld, Stefan ^a   Herzer, Kerstin ^a   Galle, Peter R ^a   Lang, Hauke ^a   Junginger, Theodor ^a   Schimanski, Carl C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Epidermal growth factor receptor; Esophageal adenocarcinoma; Esophageal squamous cell cancer; Platelet derived growth factor receptor; Vascular endothelial growth factor receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 54949130934     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000081     Document Type: Article

References (28)

1. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W and Lagergren J: Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 6: 864-870, 2005.
2. Geh JI, Crellin AM and Glynne-Jones R: Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer, Br J Surg 88: 338-356, 2001.
3. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW and van Lanschot JJ: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347: 1662-1669, 2002.
4. Li E and Hristova K: Role of receptor tyrosine kinase transmembrane domains in cell signalling and human pathologies. Biochemistry 45: 6241-6251, 2006.
5. Argraves WS and Drake CJ: Genes critical to vasculogenesis as defined by systematic analysis of vascular defects in knockout mice. Anat Rec A Discov Mol Cell Evol Biol 286: 875-884, 2005.
6. Stadler WM: Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104: 2323-2333, 2005.
7. Ria R, Vacca A, Russo F, Cirulli T, Massaia M, Tosi P, Cavo M, Guidolin D, Ribatti D and Dammacco FA: VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 92: 1438-1445, 2004.
8. Kyzas PA, Stefanou D, Batistatou A and Agnantis NJ: Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 18: 485-494, 2005.
9. Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Tsukada K and Kuwano H: Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res 22: 3977-3984, 2002.
10. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, Ronnholm R, Ramo JO, Bergman M and Salo JA: Incipient angiogenesis in Barrett's epithelium and lymphangio-genesis in Barrett's adenocarcinoma. J Clin Oncol 20: 2971-2979, 2002.
11. Kitadai Y, Amioka T, Haruma K, Tanaka S, Yoshihara M, Sumii K, Matsutani N, Yasui W and Chayama K: Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 93: 662-666, 2001.
12. Jain RK and Booth MF: What brings pericytes to tumor vessels? J Clin Invest 112: 1134-1136, 2003.
13. Lee D and Heymach JV: Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer 7: 304-308, 2006.
14. Motzer RJ, Hoosen S, Bello CL and Christensen JG: Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 15: 553-561, 2006.
15. Loges S, Clausen H, Reichelt U, Bubenheim M, Erbersdobler A, Schurr P, Yekebas E, Schuch G, Izbicki J, Pantel K, Bokemeyer C and Fiedler W: Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res 13: 76-80, 2007.
16. Zhang X, Rong TH, Zhang Y, Long H, Fu JH, Ling P, Zhang LJ, Yang MT, Zeng CG, Ma GW, Su XD, Li XD, Wang JY, Wen ZS and Zhao JM: [Expression and significance of C-kit and platelet-derived growth factor receptor-beta (PDGFRbeta) in esophageal carcinoma]. Ai Zheng 25: 92-95, 2006.
17. Zhang PY, Li BJ, Su XD, Wen ZS, Zhao JM, Zhang LJ, Long H and Rong TH: [In vitro killing effects of STI571 on esophageal carcinoma cell lines CE-48T and CE-81T]. Ai Zheng 25: 456-460, 2006.
18. Matsumoto S, Yamada Y, Narikiyo M, Ueno M, Tamaki H, Miki K, Wakatsuki K, Enomoto K, Yokotani T and Nakajima Y: Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas. Anticancer Res 27: 2409-2414, 2007.
19. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H and Grunert S: Autocrine PDGFR signalling promotes mammary cancer metastasis. J Clin Invest 116: 1561-1570, 2006.
20. Uren A, Merchant MS, Sun CJ, Vitolo MI, Sun Y, Tsokos M, Illei PB, Ladanyi M, Passaniti A, Mackall C and Toretsky JA: Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 22: 2334-2342, 2003.
21. Lasota J, Stachura J and Miettinen M: GISTs with PDGFRA exon 14 mutations represent subset of clinically favourable gastric tumors with epitheloid morphology. Lab Invest 86: 94-100, 2006.
22. Wardelmann E, Pauls K, Merkelbach-Bruse S, Hrychyk A, Losen I, Hohenberger P, Buttner R and Pietsch T: [Gastrointestinal stromal tumors carrying PDGFRalpha mutations occur preferentially in the stomach and exhibit an epithelioid or mixed phenotype]. Verh Dtsch Ges Pathol 88: 174-183, 2004.
23. Hoshino M, Fukui H, Ono Y, Sekikawa A, Ichikawa K, Tomita S, Imai Y, lmura J, Hiraishi H and Fujimori T: Nuclear expression of phosphorylated EGFR is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Pathobiology 74: 15-21, 2007.
24. Ako E, Yamashita Y, Ohira M, Yamazaki M, Hori T, Kubo N, Sawada T and Hirakawa K: The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. Oncol Rep 17: 887-893, 2007.
25. Wang KL, Wu TT, Choi IS, Wang H, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A and Albarracin CT: Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109: 658-667, 2007.
26. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H and Fujii H: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 120: 781-787, 2007.
27. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N and Ooi A: EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118: 1173-1180, 2006.
28. Drescher D, Moehler M, Gockel I, Frerichs K, Muller A, Dunschede F, Borschitz T, Biesterfeld S, Holtmann M, Wehler T, Teufel A, Herzer K, Fischer T, Berger MR, Junginger T, Galle PR and Schimanski CC: Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma - a rationale for a molecular targeting strategy? World J Gastroenterol 13: 3605-3609, 2007.